作者：情报员 国家知识产权局信息显示，玖龙纸业（重庆）有限公司取得一项名为"一种化工辅料粉体制备用高聚物 下料用漏斗"的专利，授权公告号CN116730023B，申请日期为2022年3月。 天眼查资料显示，玖龙纸业（重庆）有限公司，成立于2006年，位于重庆市，是一家以从事造纸和纸制 品业为主的企业。企业注册资本92772.846万美元。通过天眼查大数据分析，玖龙纸业（重庆）有限公 司共对外投资了1家企业，参与招投标项目117次，专利信息105条，此外企业还拥有行政许可115个。 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 本文源自：市场资讯 ...

Core Insights - The paper and paper products industry in China is projected to have 8,167 enterprises by the end of 2025, reflecting an increase of 125 enterprises compared to the previous year, which represents a year-on-year growth of 1.55% [1] Industry Overview - The number of enterprises in the paper and paper products industry has been increasing, with a total of 8,167 enterprises expected by December 2025 [1] - The growth rate of 1.55% indicates a steady expansion in the industry, contributing to 1.55% of the total industrial enterprises [1] Statistical Data - The threshold for scale enterprises in the industry has been raised from an annual main business income of 5 million to 20 million yuan since 2011 [1] - The data is sourced from the National Bureau of Statistics and compiled by Zhiyan Consulting [1]

经营范围含纸制品制造；纸制品销售；纸浆销售；塑料制品制造；塑料制品销售；卫生用品和一次性使 用医疗用品销售；物联网设备销售；物联网技术服务；人工智能硬件销售；互联网销售（除销售需要许 可的商品）；供应链管理服务；技术进出口；货物进出口；产业用纺织制成品制造；日用杂品制造；日 用品销售；日用杂品销售；日用木制品销售；日用木制品制造；竹制品制造；竹制品销售；消毒剂销售 （不含危险化学品）（除依法须经批准的项目外，凭营业执照依法自主开展经营活动） 企业名称周口诚益纸业有限公司法定代表人常利平注册资本300万人民币国标行业制造业>造纸和纸制 品业>纸制品制造地址河南省周口市鹿邑县先进制造业开发区辅仁大道西侧12号(工业园区内)企业类型 有限责任公司（非自然人投资或控股的法人独资）营业期限2026-2-11至无固定期限登记机关鹿邑县市 场监督管理局 天眼查显示，近日，周口诚益纸业有限公司成立，法定代表人为常利平，注册资本300万人民币，由海 南万戈网络科技投资有限公司全资持股。 序号股东名称持股比例1海南万戈网络科技投资有限公司100% 来源：市场资讯 ...

Group 1 - The core message highlights that the three major exchanges in China have optimized the refinancing rules for listed companies, creating a "green channel" for high-quality companies to access funds more easily for development [1] - The adjustments specifically benefit innovative enterprises by changing the criteria for recognition, facilitating their ability to secure financing [1] - Despite the positive news, market reactions can be volatile, with stocks experiencing fluctuations that may confuse investors [1] Group 2 - The article introduces two key indicators for quantitative analysis: "institutional inventory" and "dominant momentum," which simplify the understanding of stock performance [2][3] - "Institutional inventory" serves as a measure of stock activity, indicating the level of participation from large funds, while "dominant momentum" records different trading states [3] - The presence of both indicators together suggests strong involvement from large funds, indicating a more sustainable market trend [3][8] Group 3 - The article warns against mistaking retail investor activity for institutional investment, emphasizing the importance of distinguishing between the two to avoid poor investment decisions [8] - It provides examples of stocks where the presence of institutional inventory and dominant momentum indicates genuine market strength, contrasting with stocks driven by retail investors [8][11] - The analysis likens market behavior to observing a sports game, where the actions of substitutes can indicate the readiness of the main team to perform [11][15] Group 4 - The popularity of quantitative trading is attributed to its ability to capture signals of large fund activity, which can be likened to observing preparations before a concert [15] - The article encourages new investors to focus on the two core indicators without needing to understand complex mathematical formulas, making quantitative analysis more accessible [15] - By monitoring these indicators, investors can gain clearer insights into market dynamics and avoid confusion during volatile periods [15]

Group 1: New Stock Listings - Three new stocks are listed today: Linping Development on the Shanghai Stock Exchange, Dianke Lantian on the Sci-Tech Innovation Board, and Aide Technology on the Beijing Stock Exchange [1][2][5] Group 2: Linping Development - Linping Development is a leading paper manufacturing company in Anhui Province, focusing on the research, production, and sales of corrugated paper and boxboard products [1] - The company achieved revenues of 2.879 billion yuan, 2.800 billion yuan, and 2.485 billion yuan for the years 2022, 2023, and 2024 respectively, with net profits of 154 million yuan, 212 million yuan, and 153 million yuan [1] - For 2025, the company forecasts a revenue growth of 6.23% to 2.87 billion yuan and a net profit increase of 17.76% to 2.12 billion yuan [1] Group 3: Dianke Lantian - Dianke Lantian is a leader in aerospace power systems in China, with products including space solar battery arrays and lithium-ion battery packs, serving national and commercial aerospace sectors [1] - The company has become a major supplier for large satellite constellations, supporting over 700 spacecraft and covering significant national projects [1] - The aerospace power business accounted for 74% of the company's revenue, with a domestic market share exceeding 50% [1] Group 4: Aide Technology - Aide Technology specializes in the research, production, and sales of orthopedic medical devices, focusing on spinal, trauma, and sports medicine products [2][6] - The company reported revenues of 262.1 million yuan, 274.9 million yuan, and 301.7 million yuan for the years 2023, 2024, and 2025 respectively, with net profits of 63.57 million yuan, 67.13 million yuan, and 77.75 million yuan [2] - The company forecasts a revenue growth of 0.35% to 3.85 million yuan for 2025, while net profit is expected to fluctuate between -3.18% to 6.81% [2]

Group 1: Linping Development (603284.SH) - Linping Development specializes in the research, production, and sales of corrugated paper and boxboard products, recognized as a high-tech enterprise with independent R&D capabilities [4][6] - The company has a market capitalization of 28.57 billion yuan and an issue price of 37.88 yuan per share, with an issuance P/E ratio of 18.69 [4] - Linping Development's production capacity is 1.15 million tons, ranking among the top 30 paper production companies in China, with a projected raw paper output of 1.0197 million tons for 2024 [6] - The company has established stable partnerships with well-known domestic enterprises, enhancing its brand influence and competitive advantage [6] Group 2: Electric Science Blue Sky (688818.SH) - Electric Science Blue Sky focuses on advanced electric energy systems and products, with a market capitalization of 164.50 billion yuan and an issue price of 9.47 yuan per share [9] - The company has a high concentration of sales to its largest customer, Aerospace Science and Technology Group, which accounted for 45.59% of its revenue in 2022 [12] - Electric Science Blue Sky has a strong technological foundation with 367 authorized patents and has received multiple national science and technology awards [12] Group 3: Aide Technology (920180.BJ) - Aide Technology is engaged in the R&D, production, and sales of orthopedic medical devices, with a market capitalization of 7.67 billion yuan and an issue price of 7.67 yuan per share [16] - The company ranks third among domestic manufacturers of spinal vertebral body shaping systems and has a stable customer base with no single customer exceeding 50% of total sales [17] - Aide Technology holds 108 patents, including 41 invention patents, and is subject to strict regulatory oversight from health authorities [17]

Group 1 - The company, Anhui Linping Circular Development Co., Ltd., will list its common shares on the Shanghai Stock Exchange on February 10, 2026, following approval from the exchange [1] - The total share capital after the issuance will be 75,414,800 shares, with 18,853,700 shares being newly issued and publicly offered [5] - The initial public offering price is set at 37.88 yuan per share, which corresponds to a diluted price-to-earnings (P/E) ratio of 18.69 times based on the company's projected earnings for 2024 [7] Group 2 - The company operates in the "C22 Paper and Paper Products" industry, with an average static P/E ratio of 26.36 times for the industry as of January 27, 2026 [4] - The company will have a limited number of circulating shares at the time of listing, with only 1,847,340.3 shares available for trading, representing approximately 24.50% of the total share capital [3] - The stock will be subject to a price fluctuation limit of 10% after the first five trading days, which may lead to significant price volatility in the early trading period [2]

安徽林平循环发展股份有限公司 首次公开发行股票主板 上市公告书提示性公告 保荐人（主承销商）： 扫描二维码查阅公告全文 本公司及全体董事、高级管理人员保证信息披露的内容真实、准确、完整、 及时，没有虚假记载、误导性陈述或重大遗漏。 经上海证券交易所审核同意，安徽林平循环发展股份有限公司（以下简称"本 公司"、"发行人"、"公司"、"林平发展"）发行的人民币普通股股票将于 2026 年 2 月 10 日在上海证券交易所主板上市，上市公告书全文和首次公开发行股票的 招股说明书全文披露于上海证券交易所网站（http://www.sse.com.cn/）和符合中 国证监会规定条件网站（中国证券网：www.cnstock.com；中证网：www.cs.com.cn； 证券时报网：www.stcn.com；证券日报网：www.zqrb.cn；经济参考网：www.jjckb.cn; 中国金融新闻网：www.financialnews.com.cn；中国日报网：www.chinadaily.com.cn） 披露，并置备于发行人、上海证券交易所、本次发行保荐人（主承销商）国联民 生证券承销保荐有限公司的住所，供投资者查阅。 一 ...

股票简称：林平发展 股票代码：603284 安徽林平循环发展股份有限公司 Anhui Linping Circular Development Co., Ltd （萧县圣泉乡北城村） 首次公开发行股票主板上市公告书 保荐人（主承销商） （中国(上海)自由贸易试验区浦明路 8 号） 二零二六年二月九日 特别提示 安徽林平循环发展股份有限公司（以下简称"林平发展"、"本公司"或"发行 人"、"公司"）股票将于 2026 年 2 月 10 日在上海证券交易所主板上市。 本公司提醒投资者应充分了解股票市场风险以及本公司披露的风险因素，在 新股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 本上市公告书中若出现总数与各分项数值之和尾数不等的情况，均为四舍五 入尾差所致。 1 | 特别提示 1 | | --- | | 目 录 2 | | 第一节 重要声明与提示 3 | | 一、重要声明与提示 3 | | 二、主板新股上市初期投资风险特别提示 3 | | 三、特别风险提示 5 | | 第二节 股票上市情况 11 | | 一、股票发行上市审核情况 11 | | 二、股票上市相关信息 11 | | 三、公司申请首次公开 ...

Group 1 - Fulin Precision's subsidiary Jiangxi Shenghua invested 270 million yuan to establish a joint venture for a 500,000-ton ferrous oxalate project, with a total investment of 1.5 billion yuan expected to be completed by September 30, 2026 [1] - Xuguang Electronics plans to raise up to 1 billion yuan through a private placement to fund high-voltage vacuum arc extinguishing chamber expansion and other projects [2] - Minexplosion Optoelectronics intends to acquire 100% equity of Xiazhi Precision, with the transaction subject to shareholder and regulatory approvals [3] Group 2 - Shangluo Electronics' controlling shareholder plans to reduce his stake by up to 3% due to personal financial needs [4] - Babi Food reported a 1.3% decline in net profit for 2025, despite an 11.22% increase in revenue [5] - Pengding Holdings' subsidiary acquired industrial land in Huai'an for 66.14 million yuan [6] Group 3 - Zhuoyue New Energy's net profit for 2025 increased by 14.16%, despite a 17.43% decline in revenue [7] - Zhongyuan Media's net profit grew by 30.99% in 2025, with revenue decreasing by 5.13% [8] - Huangshan Tourism plans to invest approximately 530 million yuan in a hotel project with a 24-month construction period [9] Group 4 - *ST Jinling's restructuring plan was approved by the court, which may improve the company's financial situation [11] - Jichuan Pharmaceutical's subsidiary paid 80 million yuan for exclusive commercialization rights of a drug [12] - Pilin Bio's subsidiary received a notice for the acceptance of a drug supplement application [13] Group 5 - Nepe Mining terminated its investment in Swiss Veritas Resources AG due to changes in conditions [14] - Jinhui Wine announced a cash dividend of 0.20 yuan per share for the first three quarters of 2025 [15] - Hualan Biological's clinical trial for a new drug received approval for an additional indication [16] Group 6 - Industrial Fulian reported a total of 247 million yuan spent on share buybacks as of January 31, 2026 [17] - Yitong Century was pre-selected for a 107 million yuan project with China Tower [18] - Wanfeng Co. noted uncertainty in future price changes for disperse dyes [19] Group 7 - Bibet's clinical trial application for a new drug was approved by the National Medical Products Administration [21] - Chengbang Co. signed new project contracts worth 40.03 million yuan in Q4 2025 [22] - *ST Hengji received a court ruling for a performance compensation of 175 million yuan [23] Group 8 - Jihua Group is planning a change in control, leading to continued stock suspension [24] - Ningbo Port expects a container throughput of 5.03 million TEUs in January 2026, a 9.5% increase [25] - Hengli Petrochemical's actual controller increased his stake by 3.3 million shares [26] Group 9 - Hongfuhan signed a sales contract worth 480 million yuan with Guangdong Quanxiang [27] - All New Good's shareholder lifted a judicial freeze on 4.36% of the company's shares [28] - Changchun High-tech's subsidiary's clinical trial application for a new drug was accepted [29] Group 10 - Xingqi Eye Medicine's clinical trial for a new drug entered the first/second phase [31] - Hanma Technology reported a 140.04% increase in new energy heavy truck production in January 2026 [32] - Hengfeng Paper plans to invest 349 million yuan in a new green printing project [33] Group 11 - Zhifei Biological's mRNA vaccine for shingles received clinical trial approval [34] - Yutong Bus reported a 15.35% decrease in production in January 2026 [35] - StarNet Ruijie plans to sign a lease contract with an affiliate for a total rent of up to 110 million yuan [36] Group 12 - Hacheng Bonda's director completed a 0.97% share reduction [37] - Hendi Pharmaceutical's application for a new drug was approved [38] - Xinhua Medical's subsidiary received a medical device registration certificate [40] Group 13 - Yaokang Bio reported a 31.49% increase in net profit for 2025 [41] - Gaotie Electric reported a 14.02% increase in net profit for 2025 [42]